Nature of the business (Details) - USD ($) $ in Thousands		12 Months Ended
	Jan. 04, 2023	Dec. 31, 2022	Dec. 31, 2021	Oct. 14, 2021	Oct. 01, 2021
Net loss		$ 36,896	$ 24,711
Accumulated deficit		116,001	79,105
Proceeds from sales of equity and debt		125,100
Reimbursement expenses received		17,600
Securities aggregate price				$ 200,000
Cash and cash equivalents		$ 20,323	$ 49,229
Collaboration agreement with AbbVie | Subsequent events
Upfront payment	$ 30,000
Additional platform access payments	70,000
Additional upfront payment	30,000
Proceeds from non-refunded upfront payment	30,000
Collaboration agreement with AbbVie | Subsequent events | Maximum
Additional platform access payments	70,000
Development and commercial sale milestone receivable per target	120,000
Sales based milestone based on achievement	150,000
Potentially eligible amount receivable	$ 2,800
Shelf Registration Statement | Maximum
Securities aggregate price				$ 200,000
Open Market Sale | Maximum
Securities aggregate price					$ 75,000